Profile data is unavailable for this security.
About the company
Pieris Pharmaceuticals, Inc. is a biotechnology company, which discovers and develops Anticalin-based drugs to target validated disease pathways. The Company’s clinical pipeline consists of immuno-oncology (IO), bispecific in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Its Anticalin platform technology focuses on low molecular-weight Anticalin proteins that can bind tightly and specifically to a diverse range of targets. The Anticalin technology is modular, which allows it to design multimeric Anticalin based bi- and multi- specific proteins to bind with specificity to two or more targets at the same time. S095012 consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins genetically fused to each arm of the C-terminal heavy chain of the antibody.
- Revenue in USD (TTM)40.93m
- Net income in USD-16.25m
- Incorporated2013
- Employees46.00
- LocationPieris Pharmaceuticals Inc225 Franklin Street, 26Th FloorBOSTON 02110United StatesUSA
- Phone+1 (857) 246-8998
- Fax+49 (8161) 141-1444
- Websitehttps://www.pieris.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allied Corp | 21.51k | -9.00m | 12.70m | -- | -- | -- | -- | 590.33 | -0.0915 | -0.0915 | 0.0002 | -0.0711 | 0.0051 | 1.65 | 0.1441 | -- | -214.39 | -- | -- | -- | -6,919.57 | -- | -41,861.41 | -- | 0.0333 | -31.86 | -- | -- | -56.46 | -- | 31.30 | -- | -- | -- |
| Dominari Holdings Inc | 3.41m | -24.56m | 12.70m | 26.00 | -- | 0.2664 | -- | 3.73 | -4.64 | -4.64 | 0.6305 | 8.03 | 0.0539 | -- | 0.8023 | 131,000.00 | -38.88 | -26.82 | -39.93 | -27.45 | -- | -- | -721.11 | -3,353.52 | -- | -- | 0.00 | -- | -- | 135.75 | 12.72 | -- | 63.99 | -- |
| Lotus Pharmaceuticals Inc | 70.79m | 1.72m | 12.73m | 233.00 | 0.0854 | 0.0013 | 3.30 | 0.1798 | 0.0553 | 0.0553 | 2.56 | 3.58 | 0.6321 | 37.27 | 17.85 | 303,836.90 | 1.55 | 22.84 | 1.71 | 26.40 | 35.10 | 41.62 | 2.45 | 19.93 | 0.4428 | 30.80 | 0.0516 | 0.00 | 28.71 | 31.70 | -12.22 | 51.11 | 70.48 | -- |
| Plus Therapeutics Inc (USA) | 6.08m | -11.77m | 12.78m | 20.00 | -- | -- | -- | 2.10 | -3.19 | -3.19 | 1.67 | -1.13 | 0.5724 | -- | -- | 304,200.00 | -110.75 | -59.18 | -- | -133.04 | -- | -- | -193.49 | -470.45 | -- | -- | -- | -- | 2,093.30 | -5.89 | 34.32 | -- | 3.77 | -- |
| Check Cap Ltd | 0.00 | -17.62m | 12.78m | 85.00 | -- | 0.4666 | -- | -- | -3.01 | -3.01 | 0.00 | 4.68 | 0.00 | -- | -- | 0.00 | -44.86 | -58.80 | -48.21 | -66.41 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.08 | -- | 16.04 | -- |
| ELEVAI Labs Inc | 1.71m | -4.30m | 12.94m | 18.00 | -- | 3.10 | -- | 7.56 | -0.2482 | -0.2482 | 0.0988 | 0.2208 | -- | -- | -- | 95,143.89 | -- | -- | -- | -- | 66.25 | -- | -251.17 | -- | 3.41 | -41.16 | 0.00 | -- | 123.50 | -- | -138.94 | -- | -- | -- |
| Coeptis Therapeutics Holdings Inc | 0.00 | -16.31m | 13.00m | 5.00 | -- | 2.93 | -- | -- | -0.5804 | -0.5804 | 0.00 | 0.1197 | 0.00 | -- | -- | 0.00 | -212.70 | -36.90 | -378.58 | -37.81 | -- | -- | -- | -- | -- | -- | 0.349 | -- | -- | -- | 43.40 | -- | -- | -- |
| Actavia Life Sciences Inc | 0.00 | -4.44m | 13.04m | 1.00 | -- | -- | -- | -- | -0.0074 | -0.0074 | 0.00 | -0.0027 | 0.00 | -- | -- | 0.00 | -10,235.89 | -158.17 | -- | -- | -- | -- | -- | -- | -- | -21.20 | -- | -- | -- | -- | -547.04 | -- | -- | -- |
| Imunon Inc | 0.00 | -18.85m | 13.16m | 33.00 | -- | 1.55 | -- | -- | -2.02 | -2.02 | 0.00 | 0.9041 | 0.00 | -- | -- | 0.00 | -66.82 | -50.18 | -91.53 | -60.27 | -- | -- | -- | -5,725.88 | -- | -- | 0.00 | -- | -100.00 | -- | 45.64 | -- | 26.69 | -- |
| Organovo Holdings Inc | 242.00k | -19.09m | 13.38m | 15.00 | -- | 1.64 | -- | 55.29 | -2.17 | -2.17 | 0.0275 | 0.6283 | 0.0143 | -- | 4.44 | 12,100.00 | -112.40 | -51.24 | -123.59 | -54.90 | -- | -- | -7,886.36 | -1,269.78 | -- | -- | 0.00 | -- | -75.33 | -39.60 | -50.76 | -- | 5.99 | -- |
| Microbot Medical Inc | 0.00 | -10.26m | 13.54m | 22.00 | -- | 2.19 | -- | -- | -0.8926 | -0.8926 | 0.00 | 0.4283 | 0.00 | -- | -- | 0.00 | -151.13 | -53.28 | -183.85 | -62.65 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 18.44 | -- | -31.76 | -- |
| Pieris Pharmaceuticals Inc | 40.93m | -16.25m | 13.57m | 46.00 | -- | 0.6177 | -- | 0.3315 | -12.74 | -12.74 | 34.05 | 17.76 | 0.7324 | -- | 28.25 | 889,717.40 | -29.09 | -28.41 | -52.98 | -39.69 | -- | -- | -39.71 | -94.61 | -- | -- | 0.00 | -- | 65.28 | 8.03 | 26.25 | -- | -36.82 | -- |
| GlucoTrack Inc | 0.00 | -7.10m | 13.70m | 6.00 | -- | 3.27 | -- | -- | -0.3394 | -0.3394 | 0.00 | 0.153 | 0.00 | -- | -- | 0.00 | -193.30 | -94.01 | -294.60 | -142.35 | -- | -- | -- | -10,447.96 | -- | -- | 0.0578 | -- | -- | -- | -60.02 | -- | -- | -- |
| Vicapsys Life Sciences Inc | 0.00 | -1.08m | 14.24m | 2.00 | -- | -- | -- | -- | -0.0327 | -0.0327 | 0.00 | -0.0416 | 0.00 | -- | -- | 0.00 | -364.66 | -- | -- | -- | -- | -- | -- | -- | -- | -10.40 | -- | -- | -- | -- | -317.25 | -- | -- | -- |
Data as of May 20 2024. Currency figures normalised to Pieris Pharmaceuticals Inc's reporting currency: US Dollar USD
36.47%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BVF Partners LPas of 31 Mar 2024 | 257.62k | 20.83% |
| Lynx1 Capital Management LPas of 31 Mar 2024 | 109.74k | 8.87% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 17.87k | 1.45% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 12.94k | 1.05% |
| Acadian Asset Management LLCas of 31 Mar 2024 | 12.03k | 0.97% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 11.07k | 0.90% |
| Citadel Advisors LLCas of 31 Mar 2024 | 9.84k | 0.80% |
| Geode Capital Management LLCas of 31 Mar 2024 | 9.66k | 0.78% |
| CM Management LLCas of 31 Mar 2024 | 7.19k | 0.58% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 3.05k | 0.25% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
